55 published articles
TRANSCEND-CKD (NCT05936151) designates iohexol plasma clearance as its primary endpoint rather than creatinine-derived eGFR. In obesity-related CKD, creatinine equations carry systematic muscle-mass biases, and retatrutide's substantial weight reduction further shifts creatinine generation. Iohexol mGFR eliminates both noise sources, enabling the trial to detect a true pharmacological signal on kidney function.
The 2026 Mateescu Pharmaceutics review (doi:10.3390/pharmaceutics18050625) and the 2025 Vasireddi systematic review in HSS Journal converge on the same verdict: BPC-157's preclinical evidence base is extensive by volume but structurally incompatible with regulatory acceptance. Non-GLP study designs, single-group concentration, absent non-human primate data, and heterogeneous outcome measures collectively disqualify the existing literature from IND-enabling status.
The CANYON-1 Phase 1b trial enrolled 240 non-diabetic adults with obesity and reported that oral CRB-913 at 60 mg produced five percent mean weight loss from baseline at twelve weeks, with 44 percent of completers losing at least five percent and no CNS-related adverse events observed. These are Phase 1b data and Phase 2 confirmation is required.
A 2026 review in Pharmaceuticals (Sikiric et al., doi:10.3390/ph19030463) proposes cytoprotection as the mechanistic bridge reconciling BPC-157's simultaneous anti-hemorrhagic and anti-thrombotic activity in rodent models. The peptide counteracts both pathologies without measurably altering coagulation cascade parameters — aggregometry and thromboelastometry remain unchanged — pointing instead to vascular endothelial repair, nitric oxide modulation, and collateral vessel recruitment as the operative mechanisms.
The full PIONEER TEENS dataset — posted to ClinicalTrials.gov on August 21, 2026 — showed that oral semaglutide (up to 14 mg once daily) reduced HbA1c by a placebo-subtracted 0.83 percentage points at week 26 in adolescents aged 10–17 with type 2 diabetes, meeting its primary endpoint in a 52-week phase 3a RCT (NCT04596631, n=132).
TRANSCEND-CKD (NCT05936151) is a Phase 2b double-blind, placebo-controlled mechanistic trial designed to isolate retatrutide's effect on eGFR slope in adults with obesity and CKD. Its design separates acute hemodynamic dips from chronic slope, enrolls CKD stages 2–4, and stratifies by T2D status — giving it a credible structural basis for attributing eGFR changes to retatrutide. Efficacy results remain pending.
Yes — sustained semaglutide treatment activates rather than inhibits hypothalamic AgRP neurons in female mice, inverting the classical appetite-suppression model. A 2026 PNAS study by d'Ávila et al. demonstrates that AgRP neuron ablation abolishes the full weight-lowering effect of GLP-1 receptor agonists in diet-induced obese female mice, establishing these neurons as required effectors rather than suppressed bystanders.
The 2026 Mateescu Pharmaceutics review (doi:10.3390/pharmaceutics18050625) and the FDA's July 2026 PCAC briefing converge on a three-part safety problem for injectable BPC-157: synthesis impurities amplify aggregation propensity, and aggregated peptide species are established immunogenicity drivers. None of the three elements — impurity profile, aggregation behaviour, or immunogenic potential — has been formally characterised in any published pharmaceutical study.
In GLORY-1, mazdutide 6 mg produced mean body-weight change of approximately negative 15 percent versus negative 0.5 percent with placebo at 48 weeks. The placebo-subtracted treatment difference was approximately negative 14 percentage points. Orforglipron 36 mg achieved approximately negative 12 percent at 72 weeks in ATTAIN-1 but no head-to-head RCT between the two agents exists.
Yes. The EECOH-2 phase 3 trial demonstrated that once-weekly ecnoglutide at both tested doses was non-inferior to dulaglutide in HbA1c reduction over 52 weeks, with the higher dose achieving superiority. The gastrointestinal adverse-event profile was mild-to-moderate and did not exceed dulaglutide rates.
The Phase 3 LUCIDITY trial (NCT06747468), with topline data announced August 18, 2026, showed that avexitide — a first-in-class GLP-1 receptor antagonist — reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo (p=0.000003) over 16 weeks in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Amylyx plans an NDA by end of 2026.
The 2026 Mateescu Pharmaceutics review (doi:10.3390/pharmaceutics18050625) identifies a fundamental asymmetry in BPC-157's route-of-administration evidence: oral delivery has the strongest mechanistic rationale for gastrointestinal indications because luminal — not systemic — exposure is the therapeutic target, while parenteral routes face a sub-16-minute intravenous half-life and species-variable intramuscular bioavailability (14–51%) that undermine systemic exposure modelling.